Pamela Vig, Ph.D.
Pamela Vig, Ph.D., is chief scientific officer for Mirum Pharmaceuticals, where she leads the scientific and clinical aspects of drug development and research, and medical affairs.
Pam has more than 25 years of industry experience in clinical development, medical affairs and translational science in various liver diseases including HBV, HCV, NASH, and cholestatic liver disease, as well as HIV and other infectious diseases. Before joining Mirum, Pam held leadership roles at Allergan and Tobira Therapeutics as vice president of clinical research and discovery, as well as vice president of clinical research at Presidio Pharmaceuticals. Pam previously served as director, global medical affairs at Johnson & Johnson in London, UK, and also held positions in clinical resesarch and development at Idenix Pharmaceuticals and Gilead Sciences. Pam is a member of the PSC Forum Steering Committee as well as co-chair for the pediatric cholestatic disease working group under the Forum for Collaborative Research.
Pam holds a Ph.D. from Imperial College London in the departments of hepatology and histophathology.